Medical - Equipment & Services
Compare Stocks
4 / 10Stock Comparison
CON vs UNH vs CVS vs ELV
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
CON vs UNH vs CVS vs ELV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Equipment & Services | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $3.03B | $335.60B | $111.40B | $80.98B |
| Revenue (TTM) | $2.23B | $449.71B | $407.90B | $200.41B |
| Net Income (TTM) | $178M | $12.04B | $2.93B | $5.24B |
| Gross Margin | 28.7% | 18.8% | 13.9% | 23.2% |
| Operating Margin | 89.9% | 4.2% | 1.5% | 3.8% |
| Forward P/E | 16.2x | 20.2x | 12.2x | 13.9x |
| Total Debt | $2.10B | $78.39B | $93.59B | $33.23B |
| Cash & Equiv. | $80M | $24.36B | $8.51B | $9.49B |
CON vs UNH vs CVS vs ELV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 24 | May 26 | Return |
|---|---|---|---|
| Concentra Group Hol… (CON) | 100 | 101.3 | +1.3% |
| UnitedHealth Group … (UNH) | 100 | 64.2 | -35.8% |
| CVS Health Corporat… (CVS) | 100 | 144.7 | +44.7% |
| Elevance Health Inc. (ELV) | 100 | 70.1 | -29.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CON vs UNH vs CVS vs ELV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CON is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 13.9%, EPS growth 0.0%, 3Y rev CAGR 7.9%
- 13.9% revenue growth vs CVS's 7.8%
- 8.0% margin vs CVS's 0.7%
- 6.1% ROA vs CVS's 1.1%, ROIC 69.4% vs 5.0%
UNH is the clearest fit if your priority is long-term compounding.
- 220.6% 10Y total return vs ELV's 202.1%
CVS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Lower P/E (12.2x vs 13.9x)
- Beta 0.05 vs CON's 0.69, lower leverage
ELV is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.46, Low D/E 75.5%, current ratio 1.24x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.9% revenue growth vs CVS's 7.8% | |
| Value | Lower P/E (12.2x vs 13.9x) | |
| Quality / Margins | 8.0% margin vs CVS's 0.7% | |
| Stability / Safety | Beta 0.05 vs CON's 0.69, lower leverage | |
| Dividends | 3.1% yield, vs UNH's 2.4% | |
| Momentum (1Y) | +34.7% vs ELV's -9.0% | |
| Efficiency (ROA) | 6.1% ROA vs CVS's 1.1%, ROIC 69.4% vs 5.0% |
CON vs UNH vs CVS vs ELV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CON vs UNH vs CVS vs ELV — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CVS leads in 3 of 6 categories
CON leads 2 • UNH leads 0 • ELV leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
CON leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 201.5x CON's $2.2B. CON is the more profitable business, keeping 8.0% of every revenue dollar as net income compared to CVS's 0.7%. On growth, CON holds the edge at +13.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $2.2B | $449.7B | $407.9B | $200.4B |
| EBITDAEarnings before interest/tax | $2.1B | $23.2B | $10.5B | $8.9B |
| Net IncomeAfter-tax profit | $178M | $12.0B | $2.9B | $5.2B |
| Free Cash FlowCash after capex | $293M | $19.7B | $7.4B | $6.5B |
| Gross MarginGross profit ÷ Revenue | +28.7% | +18.8% | +13.9% | +23.2% |
| Operating MarginEBIT ÷ Revenue | +89.9% | +4.2% | +1.5% | +3.8% |
| Net MarginNet income ÷ Revenue | +8.0% | +2.7% | +0.7% | +2.6% |
| FCF MarginFCF ÷ Revenue | +13.1% | +4.4% | +1.8% | +3.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +13.7% | +2.0% | +6.2% | +2.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +25.8% | +0.7% | +63.1% | -16.8% |
Valuation Metrics
CVS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 14.8x trailing earnings, ELV trades at a 76% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, CON's 2.3x EV/EBITDA is more attractive than UNH's 16.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $3.0B | $335.6B | $111.4B | $81.0B |
| Enterprise ValueMkt cap + debt − cash | $5.1B | $389.6B | $196.5B | $104.7B |
| Trailing P/EPrice ÷ TTM EPS | 18.16x | 27.95x | 62.81x | 14.84x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.18x | 20.19x | 12.19x | 13.93x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 2.15x |
| EV / EBITDAEnterprise value multiple | 2.34x | 16.70x | 13.11x | 10.84x |
| Price / SalesMarket cap ÷ Revenue | 1.40x | 0.75x | 0.28x | 0.41x |
| Price / BookPrice ÷ Book value/share | 7.20x | 3.31x | 1.47x | 1.88x |
| Price / FCFMarket cap ÷ FCF | 15.40x | 20.88x | 14.27x | 25.51x |
Profitability & Efficiency
CON leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
CON delivers a 43.7% return on equity — every $100 of shareholder capital generates $44 in annual profit, vs $4 for CVS. ELV carries lower financial leverage with a 0.75x debt-to-equity ratio, signaling a more conservative balance sheet compared to CON's 5.00x. On the Piotroski fundamental quality scale (0–9), UNH scores 6/9 vs CVS's 5/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +43.7% | +11.5% | +3.9% | +11.9% |
| ROA (TTM)Return on assets | +6.1% | +3.9% | +1.1% | +4.3% |
| ROICReturn on invested capital | +69.4% | +9.2% | +5.0% | +9.1% |
| ROCEReturn on capital employed | +84.9% | +9.7% | +6.1% | +8.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 6 |
| Debt / EquityFinancial leverage | 5.00x | 0.77x | 1.24x | 0.75x |
| Net DebtTotal debt minus cash | $2.0B | $54.0B | $85.1B | $23.7B |
| Cash & Equiv.Liquid assets | $80M | $24.4B | $8.5B | $9.5B |
| Total DebtShort + long-term debt | $2.1B | $78.4B | $93.6B | $33.2B |
| Interest CoverageEBIT ÷ Interest expense | 4.59x | 4.71x | 2.11x | 5.39x |
Total Returns (Dividends Reinvested)
CVS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CVS five years ago would be worth $11,700 today (with dividends reinvested), compared to $9,743 for UNH. Over the past 12 months, CVS leads with a +34.7% total return vs ELV's -9.0%. The 3-year compound annual growth rate (CAGR) favors CVS at 11.0% vs UNH's -7.1% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +22.0% | +10.6% | +10.6% | +5.8% |
| 1-Year ReturnPast 12 months | +9.1% | -3.2% | +34.7% | -9.0% |
| 3-Year ReturnCumulative with dividends | +6.7% | -19.9% | +36.6% | -15.6% |
| 5-Year ReturnCumulative with dividends | +6.7% | -2.6% | +17.0% | +1.5% |
| 10-Year ReturnCumulative with dividends | +6.7% | +220.6% | +3.5% | +202.1% |
| CAGR (3Y)Annualised 3-year return | +2.2% | -7.1% | +11.0% | -5.5% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than CON's 0.69 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs ELV's 87.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.69x | 0.59x | 0.05x | 0.46x |
| 52-Week HighHighest price in past year | $24.68 | $395.52 | $88.63 | $424.24 |
| 52-Week LowLowest price in past year | $18.55 | $234.60 | $58.35 | $273.71 |
| % of 52W HighCurrent price vs 52-week peak | +95.6% | +93.5% | +98.5% | +87.9% |
| RSI (14)Momentum oscillator 0–100 | 56.1 | 75.9 | 69.3 | 75.5 |
| Avg Volume (50D)Average daily shares traded | 654K | 7.9M | 7.4M | 1.9M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CON as "Buy", UNH as "Buy", CVS as "Buy", ELV as "Buy". Consensus price targets imply 31.3% upside for CON (target: $31) vs 2.5% for ELV (target: $382). For income investors, CVS offers the higher dividend yield at 3.06% vs CON's 1.06%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $31.00 | $385.43 | $95.20 | $382.38 |
| # AnalystsCovering analysts | 4 | 52 | 41 | 37 |
| Dividend YieldAnnual dividend ÷ price | +1.1% | +2.4% | +3.1% | +1.8% |
| Dividend StreakConsecutive years of raises | 0 | 25 | 0 | 15 |
| Dividend / ShareAnnual DPS | $0.25 | $8.70 | $2.67 | $6.89 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | +1.7% | 0.0% | +3.2% |
CVS leads in 3 of 6 categories (Valuation Metrics, Total Returns). CON leads in 2 (Income & Cash Flow, Profitability & Efficiency). 1 tied.
CON vs UNH vs CVS vs ELV: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CON or UNH or CVS or ELV a better buy right now?
For growth investors, Concentra Group Holdings Parent, Inc.
(CON) is the stronger pick with 13. 9% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Elevance Health Inc. (ELV) offers the better valuation at 14. 8x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate Concentra Group Holdings Parent, Inc. (CON) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CON or UNH or CVS or ELV?
On trailing P/E, Elevance Health Inc.
(ELV) is the cheapest at 14. 8x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — CON or UNH or CVS or ELV?
Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +17.
0%, compared to -2. 6% for UnitedHealth Group Incorporated (UNH). Over 10 years, the gap is even starker: UNH returned +220. 6% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CON or UNH or CVS or ELV?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Concentra Group Holdings Parent, Inc. 's 0. 69β — meaning CON is approximately 1263% more volatile than CVS relative to the S&P 500. On balance sheet safety, Elevance Health Inc. (ELV) carries a lower debt/equity ratio of 75% versus 5% for Concentra Group Holdings Parent, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CON or UNH or CVS or ELV?
By revenue growth (latest reported year), Concentra Group Holdings Parent, Inc.
(CON) is pulling ahead at 13. 9% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Concentra Group Holdings Parent, Inc. grew EPS 0. 0% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, UNH leads at 11. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CON or UNH or CVS or ELV?
Concentra Group Holdings Parent, Inc.
(CON) is the more profitable company, earning 8. 0% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 8. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CON leads at 96. 5% versus 2. 6% for CVS. At the gross margin level — before operating expenses — CON leads at 28. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CON or UNH or CVS or ELV more undervalued right now?
On forward earnings alone, CVS Health Corporation (CVS) trades at 12.
2x forward P/E versus 20. 2x for UnitedHealth Group Incorporated — 8. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CON: 31. 3% to $31. 00.
08Which pays a better dividend — CON or UNH or CVS or ELV?
All stocks in this comparison pay dividends.
CVS Health Corporation (CVS) offers the highest yield at 3. 1%, versus 1. 1% for Concentra Group Holdings Parent, Inc. (CON).
09Is CON or UNH or CVS or ELV better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 5%, CON: +6. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CON and UNH and CVS and ELV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CON is a small-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; ELV is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.